



June 22, 2015

ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial

LOS ANGELES, June 22, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the agreement, Pure MHC will develop and validate a new assay specifically created for ICT-107, a dendritic-cell based immunotherapy targeting six antigens found on glioblastoma cells, especially stem cells. The new assay will be used to validate the quality and confirm the activity of ICT-107 and allow it to be released for administration to patients in the phase 3 trial.



"The agreement with Pure MHC is another important milestone in ImmunoCellular's progress toward the phase 3 registration trial for ICT-107," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "Designing a new release assay to support the specific requirements of the ICT-107 six-antigen complex requires special skill and expertise, and we are confident in Pure MHC's ability to deliver a validated release assay. We believe that the knowledge and know-how gained from developing this assay can be applied to our other dendritic cell-based immunotherapy programs, thus representing a meaningful return on investment for our Company. We look forward to continuing to advance toward beginning patient enrollment in the phase 3 trial of ICT-107 in the late third quarter or early fourth quarter of this year."

"Pure MHC has developed a suite of platform technologies in the field of immuno-oncology including the use of TCRm mAb to validate peptide vaccine delivery," said Tommy Harlan, Pure MHC Chief Executive Officer. "Pure MHC looks forward to using its patented TCRm potency assay to support the release of ImmunoCellular's ICT-107 dendritic cell-based immunotherapy for glioblastoma."

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized and the potential timing for the initiation of registrational phase 3 study for this molecule. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Pure MHC

Pure MHC, LLC is a platform technology company under the scientific leadership of William Hildebrand, PhD, with expertise in disease-specific target identification, and validation as well as immunotherapeutic drug development for cancer, infectious, and autoimmune diseases as well as allergy. Pure MHC identifies and leverages the same disease targets for drug discovery that the immune system naturally uses to identify foreign or aberrant protein targets in cancerous, infected, or unhealthy cells. Pure MHC was formed and is managed by Austin-based innovations solutions company, Emergent Technologies, Inc. For more information please visit www.puremhc.com.

Contact:

For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com

Logo - <http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/immunocellular-therapeutics-establishes-agreement-with-pure-mhc-for-novel-quality-control-assay-for-ict-107-phase-3-registrational-trial-300101808.html>

SOURCE ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media